JB

Josh Baltzell

Venture Partner

KL

Kenneth Lloyd Benson

General Partner

BB

Buzz Benson

MD

Joe Biller

MD

KP

Kunal Paymaster

MD

SW

Scott Ward

General Partner

22 past transactions

Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’s intellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending. It was incorporated in 2011 and is based in Seattle, Washington.

Anulex Technologies

Series D in 2009
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

EarLens

Series C in 2017
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

CVRx, Inc.

Series D in 2007
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

Vapotherm

Series C in 2015
Vapotherm, Inc. is a privately held company based in Exeter, New Hampshire, dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification.

Conventus Orthopaedics

Venture Round in 2013
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

Celleration Inc.

Series E in 2011
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.

Anulex Technologies

Series C in 2006
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’s intellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending. It was incorporated in 2011 and is based in Seattle, Washington.

BRONCUS MEDICAL INC.

Series F in 2006
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

BRONCUS MEDICAL INC.

Series G in 2008
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Atritech

Series D in 2007
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.

Vapotherm

Series D in 2017
Vapotherm, Inc. is a privately held company based in Exeter, New Hampshire, dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification.

CVRx, Inc.

Series E in 2008
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

PHT Corporation

Series F in 2008
PHT is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in clinical trials around the world and a rapidly growing organization. Their proven LogPad and StudyPad Systems improve data quality while Their robust StudyWorks online portal provides study sponsors, monitors and sites with real-time access to the data. With PHT, biopharmaceutical and medical device companies get better data, more data, and make faster decisions - resulting in successful trials.

Verax Biomedical

Series B in 2005
Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.

LipoScience

Series F in 2006
LipoScience is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered.

Conventus Orthopaedics

Series A in 2014
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

Vapotherm

Series D in 2018
Vapotherm, Inc. is a privately held company based in Exeter, New Hampshire, dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification.

Monteris Medical, Inc.

Series C in 2017
Monteris Medical is a medical device venture that develops new technologies for the treatment of cancer. It is a private equity-backed neurosurgical company focused solely on diseases of the brain. It develops MRI-guided, laser-based systems designed for the ablation of brain lesions. The company's system applies focused laser energy to ablate brain tumors from the inside, with little or no effect on surrounding healthy tissue as well as provides clinicians a new neurosurgical tool that offers real-time control and visualization of the therapy during laser ablation treatment, enabling neurosurgeons to ablate (treat with lethal heat) brain lesions and brain tumors that may be difficult to approach via traditional methods. It was founded in 1999 and has offices in Minneapolis, Minnesota, USA and Winnipeg, Manitoba, Canada.

CVRx, Inc.

Series F in 2013
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.